1. All Products
  2. LPV / r 400/100mg/5ml, oral sol., 60ml, bot.
Public Pricelist

LPV / r 400/100mg/5ml, oral sol., 60ml, bot.

https://unicat.msf.org/cat/product/12133
NST DORALPVR2S-

Valid Article

Former Code(s): DORALPRF8S2 DORAMISC552 DORAZFR0552
6.4.2.3 - Protease inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
S
The order of this product needs to be justified and is only acceptable under certain conditions.
0208
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

    This combination does not exist.

    Add article to list

       
    Create Cancel

    Add Kit To Wishlist

       
    Create Cancel

    LOPINAVIR (LPV) / RITONAVIR (r)

    Reference List

    Therapeutic Action

    Fixed-dose combination (FDC) of two antiretrovirals, protease inhibitors (PI)

    Indications

    HIV infection, in combination with other antiretroviral drugs

    Instructions for use

    Granules in sachet are intended for paediatric use.

    Pellets-in-a-capsule and oral solutions presentations became non-standard according to the WHO 2021 Optimal formulary and Limited-use list for antiretroviral drugs for children:

    • oral granules can be used from two weeks (instead of three months) and are easier to administer compared to oral pellets
    • with increasing use of integrase inhibitor–based regimens and a preference for granules, oral solution should no longer be required

    Storage

    Below 25ºC - Protect from sunlight - Protect from humidity